Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Asunercept - Apogenix

Drug Profile

Asunercept - Apogenix

Alternative Names: APG-101; Apocept; Asinercept; CAN-008

Latest Information Update: 28 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apogenix
  • Developer Apogenix; CANbridge Pharmaceuticals; University Hospital Heidelberg
  • Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant fusion proteins
  • Mechanism of Action Apoptosis inhibitors; Fas ligand protein inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma; Myelodysplastic syndromes; Graft-versus-host disease
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma; Myelodysplastic syndromes

Highest Development Phases

  • Phase II Glioblastoma
  • No development reported Graft-versus-host disease; Myelodysplastic syndromes; Myocardial infarction; Solid tumours; Stroke

Most Recent Events

  • 28 Oct 2019 No recent reports of development identified for preclinical development in Solid-tumours in Germany (Parenteral)
  • 19 Nov 2018 CANbridge Life Sciences plans a phase II trial for Glioblastoma multiforme (Recurrent, Second line therapy or greater) in China (IV) (NCT03746288)
  • 01 Sep 2018 CANbridge Life Sciences completes a phase I/II trial in Glioblastoma (Newly diagnosed, Combination therapy) in Taiwan (IV) (NCT02853565)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top